Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers.

Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers. J Crohns Colitis. 2019 Mar 19;: Authors: Zhou H, Xi L, Ziemek D, O’Neil S, Lee J, Stewart Z, Zhan Y, Zhao S, Zhang Y, Page K, Huang A, Maciejewski M, Zhang B, Gorelick KJ, Fitz L, Pradhan V, Cataldi F, Vincent M, Von Schack D, Hung K, Hassan-Zahraee M Abstract BACKGROUND AND AIMS: To define pharmacodynamic and efficacy biomarkers in ulcerative colitis [UC] patients treated with PF-00547659, an anti-human mucosal addressin cell adhesion molecule-1 [MAdCAM-1]…

Read More

Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation? Reply from authors.

Related Articles Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation? Reply from authors. Gut. 2019 Mar 20;: Authors: Frolkis AD, Vallerand IA, Patten SB, Kaplan GG PMID: 30894399 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30894399?dopt=Abstract

Read More

Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.

Related Articles Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis. Aliment Pharmacol Ther. 2019 Mar 20;: Authors: Olaisen M, Spigset O, Flatberg A, Granlund AVB, Brede WR, Albrektsen G, Røyset ES, Gilde B, Sandvik AK, Martinsen TC, Fossmark R Abstract BACKGROUND: 5-aminosalicylic acid (5-ASA) is the first-line therapy for ulcerative colitis (UC). 5-ASA acts locally in the colonic mucosa by numerous proposed mechanisms, and is metabolised by N-acetyltransferase (NAT). Large variations in mucosal 5-ASA concentrations have been reported, but the underlying mechanisms are…

Read More

Early combined immunosuppression may be effective and safe in older patients with Crohn’s disease: post hoc analysis of REACT.

Related Articles Early combined immunosuppression may be effective and safe in older patients with Crohn’s disease: post hoc analysis of REACT. Aliment Pharmacol Ther. 2019 Mar 19;: Authors: Singh S, Stitt LW, Zou G, Khanna R, Dulai PS, Sandborn WJ, Feagan BG, Jairath V Abstract BACKGROUND: Physicians may be reluctant to prescribe combined immunosuppression in older patients with Crohn’s disease due to perceived risk of treatment-related complications. AIM: To evaluate the impact of age on risk of Crohn’s disease-related complications in patients treated with early combined immunosuppression vs conventional management…

Read More

The cost-effectiveness of biological therapy cycles in the management of Crohn’s disease.

The cost-effectiveness of biological therapy cycles in the management of Crohn’s disease. J Crohns Colitis. 2019 Mar 20;: Authors: Bolin K, Hertervig E, Louis E Abstract OBJECTIVES: to examine the cost-effectiveness of continued treatment for patients with moderate-severe Crohn’s disease in clinical remission, with a combination of anti-TNFα (infliximab) and immunomodulator therapy compared to two different withdrawal strategies (1) withdrawal of the anti-TNFα therapy, and (2) withdrawal of the immunomodulator therapy, respectively. MATERIAL AND METHODS: A decision-tree model was constructed mimicking three treatment arms: (1) continued combination therapy with infliximab…

Read More

Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients.

Related Articles Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients. World J Gastroenterol. 2019 Mar 14;25(10):1266-1277 Authors: Foster AJ, Smyth M, Lakhani A, Jung B, Brant RF, Jacobson K Abstract BACKGROUND: Asymptomatic children with Crohn’s disease (CD) require ongoing monitoring to ensure early recognition of a disease exacerbation. AIM: In a cohort of pediatric CD patients, we aimed to assess the utility of serial fecal calprotectin measurements to detect intestinal inflammatory activity and predict disease relapse. METHODS: In this prospective longitudinal cohort study, children with CD…

Read More

The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease.

The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Mar 19;: Authors: Lewis K, Marrie RA, Bernstein CN, Graff LA, Patten SB, Sareen J, Fisk JD, Bolton JM, CIHR Team in Defining the Burden and Managing the Effects of Immune-Mediated Inflammatory Disease Abstract BACKGROUND: Inflammatory bowel disease (IBD) is associated with a high prevalence of comorbid depressive and anxiety disorders. A significant proportion of IBD patients with comorbid psychiatric disorders remain undiagnosed and untreated, but factors associated with…

Read More

Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases.

Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases. J Crohns Colitis. 2019 Mar 19;: Authors: Borren NZ, Luther J, Colizzo FP, Garber JG, Khalili H, Ananthakrishnan AN Abstract BACKGROUND AND AIMS: Methotrexate [MTX] is a well-known immunomodulator in the treatment of inflammatory bowel disease [IBD] and is often combined with biologic agents. The ideal MTX dose for combination therapy has not been determined. This study aimed to investigate the effect of varying doses of MTX on efficacy and safety outcomes when…

Read More

The Inflammatory Bowel Disease Drug Azathioprine Induces Autophagy via mTORC1 and the Unfolded Protein Response Sensor PERK.

The Inflammatory Bowel Disease Drug Azathioprine Induces Autophagy via mTORC1 and the Unfolded Protein Response Sensor PERK. Inflamm Bowel Dis. 2019 Mar 19;: Authors: Hooper KM, Casanova V, Kemp S, Staines KA, Satsangi J, Barlow PG, Henderson P, Stevens C Abstract BACKGROUND: Genetic studies have strongly linked autophagy to Crohn’s disease (CD), and stimulating autophagy in CD patients may be therapeutically beneficial. The aim of this study was to evaluate the effect of current inflammatory bowel disease (IBD) drugs on autophagy and investigate molecular mechanisms of action and functional outcomes…

Read More

Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT).

Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT). J Clin Gastroenterol. 2019 Mar 13;: Authors: Allegretti JR, Kassam Z, Fischer M, Kelly C, Chan WW Abstract BACKGROUND: Fecal microbiota transplantation (FMT) is a promising therapy for recurrent Clostridioides difficile infection (CDI). Many patients report altered bowel habits including constipation, bloating, gas and loose stool post-FMT despite resolution of CDI, and the etiology remains unclear. METHODS: This was a prospective cohort study of adult patients with recurrent CDI who underwent FMT (1) via…

Read More
<< Go Back